These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 11403096

  • 1. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol.
    Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S.
    Endocr J; 2001 Feb; 48(1):11-8. PubMed ID: 11403096
    [Abstract] [Full Text] [Related]

  • 2. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial.
    Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW.
    Clin Interv Aging; 2014 Feb; 9():121-7. PubMed ID: 24426779
    [Abstract] [Full Text] [Related]

  • 3. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.
    Yonemura K, Kimura M, Miyaji T, Hishida A.
    Calcif Tissue Int; 2000 Feb; 66(2):123-8. PubMed ID: 10652960
    [Abstract] [Full Text] [Related]

  • 4. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis.
    Shiraki M, Shiraki Y, Aoki C, Miura M.
    J Bone Miner Res; 2000 Mar; 15(3):515-21. PubMed ID: 10750566
    [Abstract] [Full Text] [Related]

  • 5. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.
    Rianthavorn P, Pisutikul K, Deekajorndech T, Tepmongkol S, Suphapeetiporn K.
    J Pediatr Endocrinol Metab; 2012 Mar; 25(3-4):307-12. PubMed ID: 22768661
    [Abstract] [Full Text] [Related]

  • 6. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine.
    Yonemura K, Fukasawa H, Fujigaki Y, Hishida A.
    Am J Kidney Dis; 2004 Jan; 43(1):53-60. PubMed ID: 14712427
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women.
    Binkley N, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J.
    J Bone Miner Res; 2009 Jun; 24(6):983-91. PubMed ID: 19113922
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
    Takeda S, Kaneoka H, Saito T.
    Mod Rheumatol; 2008 Jun; 18(3):271-6. PubMed ID: 18427724
    [Abstract] [Full Text] [Related]

  • 15. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
    Ikeda T, Maruyama K, Kaji H, Akagi M.
    Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
    [Abstract] [Full Text] [Related]

  • 16. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 17. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T.
    J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases.
    Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S.
    Intern Med; 2016 Jul; 55(15):1997-2003. PubMed ID: 27477405
    [Abstract] [Full Text] [Related]

  • 19. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
    Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M.
    Aliment Pharmacol Ther; 2009 Feb 15; 29(4):424-30. PubMed ID: 19035979
    [Abstract] [Full Text] [Related]

  • 20. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover.
    Conway SP, Wolfe SP, Brownlee KG, White H, Oldroyd B, Truscott JG, Harvey JM, Shearer MJ.
    Pediatrics; 2005 May 15; 115(5):1325-31. PubMed ID: 15867043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.